Highlights

  • Clinuvel shares rose 2.16% to AUD 9.00 on 24 April 2026 following a regulatory update.
  • The company received final scientific advice from the European Medicines Agency for its Phase III vitiligo study.
  • The EMA endorsed a “totality of evidence” approach to evaluate SCENESSE.
  • The planned CUV107 study will include approximately 300 patients and is expected to commence in the second half of 2026.
  • Patient-reported outcomes and photographic evidence will play a role in evaluating treatment efficacy.

Clinuvel Pharmaceuticals Ltd (ASX:CUV) shares increased 2.16% to AUD 9.00 during the afternoon session on 24 April 2026, following the release of an update regarding its clinical development program. Despite the gain, the stock remains down 18.26% over the past year, indicating ongoing investor focus on the company’s pipeline progress and regulatory developments.

The share price movement comes after Clinuvel announced that it has received final scientific advice from the European Medicines Agency (EMA) concerning the design of its planned pivotal Phase III study (CUV107) evaluating SCENESSE (afamelanotide) as a systemic treatment for vitiligo.

Clinuvel Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, and systemic conditions, as well as acute and life-threatening disorders. The company has established a position in photomedicine, with its research centred on melanocortin peptides and related therapies aimed at photoprotection, DNA repair, and repigmentation.

EMA Provides Guidance on Phase III Study Design

Following more than 12 months of engagement, including formal submissions and a discussion meeting with the EMA’s Scientific Advice Working Party and the Committee for Medicinal Products for Human Use, Clinuvel received guidance on its vitiligo program.

The EMA indicated that the evaluation of SCENESSE for vitiligo should be based on a “totality of evidence” approach. Under this framework, the primary endpoint of the CUV107 study will be T-VASI50, which measures the proportion of patients achieving at least 50% repigmentation of the total body, excluding specific areas.

In addition to the primary endpoint, the regulatory assessment will incorporate patient-reported outcomes and clinical data from other vitiligo studies involving SCENESSE. These components are expected to contribute to the overall evaluation of both efficacy and safety when data is submitted for potential marketing authorisation.

The EMA also emphasised the importance of patient perspectives, noting that assessments by individuals with vitiligo will play a role in evaluating visible changes in pigmentation.

Photographic Evidence and Clinical Measures Integrated

A key aspect of the study design includes the use of photographic evidence to assess changes from baseline. This method will support both primary and secondary endpoints, including T-VASI50 and F-VASI75, which measures the proportion of patients achieving at least 75% repigmentation in specific regions such as the head and neck.

The study will incorporate multiple patient and physician surveys to capture patient-reported outcomes. In total, five surveys are planned, contributing additional data points to assess treatment impact from both clinical and patient perspectives.

This combination of photographic analysis, clinical endpoints, and patient feedback is intended to provide a comprehensive dataset for regulatory evaluation.

Study Design and Patient Population

The planned Phase III CUV107 study will compare SCENESSE in combination with narrowband ultraviolet B (NB-UVB) therapy against NB-UVB monotherapy. This comparative design aims to assess the added benefit of SCENESSE when used alongside an established treatment approach.

The study is expected to enrol approximately 300 participants and is scheduled to commence in the second half of 2026.

The EMA highlighted that patients with darker skin types may experience more noticeable benefits from systemic treatment due to the contrast between affected and unaffected skin areas. As a result, this patient group is expected to be an important focus in the evaluation process.

Management Commentary on Regulatory Progress

Clinuvel noted that the process of engaging with the EMA extended over a year and resulted in a defined position from the regulatory body regarding the company’s vitiligo program.

According to the company, the discussions led to several key outcomes, including agreement on study design, recognition of the importance of photographic evidence, and the adoption of the “totality of evidence” approach for final evaluation.

The company also indicated that the EMA has developed a comprehensive understanding of the SCENESSE program and its potential application in vitiligo.

About Vitiligo and Treatment Landscape

Vitiligo is described as a multifactorial condition that can involve immune-related components, leading to the progressive loss of skin pigmentation. The condition can have a notable impact on quality of life due to visible changes in skin appearance.

It is estimated to affect approximately 0.5% to 2% of the global population. Currently, there are no approved therapies specifically targeting patients with extensive depigmentation affecting more than 10% of total body surface area.

Clinuvel’s program aims to explore SCENESSE as a systemic treatment option in this setting, with the Phase III study representing a step in the clinical development pathway.

Company Background and Existing Therapy

Clinuvel’s lead therapy, SCENESSE (afamelanotide 16mg), is already approved for commercial distribution in multiple regions, including Europe, the United States, Israel, and Australia. It is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria.

The company operates globally, with headquarters in Melbourne and additional operations in Europe, Singapore, and the United States.

Its broader pipeline includes therapies and healthcare solutions aimed at specialised patient populations, with a continued focus on areas where limited treatment options are available.

What This Means for Investors?

The recent share price movement reflects investor attention on regulatory progress within Clinuvel’s clinical pipeline. The receipt of final scientific advice from the EMA provides clarity on the design and evaluation framework for the Phase III vitiligo study.

The outlined approach, including the use of combined clinical, photographic, and patient-reported data, sets the structure for how efficacy and safety will be assessed in future submissions.

At the same time, the company remains in the clinical development phase for this indication, with key milestones including the commencement of the CUV107 study and subsequent trial outcomes.

With the stock still lower over the past year, market participants appear to be monitoring how these developments translate into clinical progress and potential regulatory pathways.